Literature DB >> 18648931

Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.

Cyrille Grandjean1, Alain Boutonnier, Bruno Dassy, Jean-Michel Fournier, Laurence A Mulard.   

Abstract

A free amino group present on the acid-detoxified lipopolysaccharide (pmLPS) of V. cholerae O1 serotype Inaba was investigated for site-specific conjugation. Chemoselective pmLPS biotinylation afforded the corresponding mono-functionalized derivative, which retained antigenicity. Thus, pmLPS was bound to carrier proteins using thioether conjugation chemistry. Induction of an anti-LPS antibody (Ab) response in BALB/c mice was observed for all conjugates. Interestingly, the sera had vibriocidal activity against both Ogawa and Inaba strains opening the way to a possible bivalent vaccine. However, the level of this Ab response was strongly affected by both the nature of the linker and of the carrier. Furthermore, no switch from IgM to IgG, i.e. from a T cell-independent to a T cell-dependent immune response was detected, a result tentatively explained by the possible presence of free polysaccharide in the formulation. Taken together, these results encourage further investigation towards the development of potent pmLPS-based neoglycoconjugate immunogens, fully aware of the challenge faced in the development of a cholera vaccine that will provide efficient serogroup coverage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18648931     DOI: 10.1007/s10719-008-9160-6

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  63 in total

Review 1.  Polyosides (encapsulated bacteria).

Authors:  A A Lindberg
Journal:  C R Acad Sci III       Date:  1999-11

2.  Mass spectrometric analysis of Klebsiella pneumoniae ssp. pneumoniae rough strain R20 (O1-: K20-) lipopolysaccharide preparations: identification of novel core oligosaccharide components and three 3-deoxy-D-manno-oct-2-ulopyranosonic artifacts.

Authors:  M M Olsthoorn; J Haverkamp; J E Thomas-Oates
Journal:  J Mass Spectrom       Date:  1999-06       Impact factor: 1.982

3.  The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests.

Authors:  W H Mosley; W E Woodward; K M Aziz; A S Rahman; A K Chowdhury; A Ahmed; J C Feeley
Journal:  J Infect Dis       Date:  1970-05       Impact factor: 5.226

4.  Preparation and evaluation of vibrio cholerae O1 EL Tor Ogawa lipopolysaccharide-tetanus toxoid conjugates.

Authors:  Osmir Cabrera; Miguel E Martínez; Maribel Cuello; Carmen R Soto; Tania Valmaseda; Bárbara Cedré; Gustavo Sierra González
Journal:  Vaccine       Date:  2006-04-12       Impact factor: 3.641

5.  Common lipopolysaccharide specificity: new type of antigen residing in the inner core region of S- and R-form lipopolysaccharides from different families of gram-negative bacteria.

Authors:  H Brade; C Galanos
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

Review 6.  Vaccines based on the cell surface carbohydrates of pathogenic bacteria.

Authors:  Christopher Jones
Journal:  An Acad Bras Cienc       Date:  2005-05-09       Impact factor: 1.753

7.  Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease.

Authors:  Karen Wright; Catherine Guerreiro; Isabelle Laurent; Françoise Baleux; Laurence A Mulard
Journal:  Org Biomol Chem       Date:  2004-04-26       Impact factor: 3.876

8.  Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates.

Authors:  J M Peeters; T G Hazendonk; E C Beuvery; G I Tesser
Journal:  J Immunol Methods       Date:  1989-06-02       Impact factor: 2.303

9.  Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh--three years of observation.

Authors:  W H Mosley; K M Aziz; A S Rahman; A K Chowdhury; A Ahmed
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

10.  Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHO.

Authors:  Claire-Lise Chaignat; Victoria Monti
Journal:  J Health Popul Nutr       Date:  2007-06       Impact factor: 2.000

View more
  6 in total

1.  Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

Authors:  F O Eko; D N Okenu; U P Singh; Q He; C Black; J U Igietseme
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

2.  Determination of the glycation sites of Bacillus anthracis neoglycoconjugate vaccine by MALDI-TOF/TOF-CID-MS/MS and LC-ESI-QqTOF-tandem mass spectrometry.

Authors:  Farid Jahouh; Shu-jie Hou; Pavol Kováč; Joseph H Banoub
Journal:  J Mass Spectrom       Date:  2011-10       Impact factor: 1.982

3.  Conjugate Vaccines from Bacterial Antigens by Squaric Acid Chemistry: A Closer Look.

Authors:  Peng Xu; Meagan Kelly; Willie F Vann; Firdausi Qadri; Edward T Ryan; Pavol Kováč
Journal:  Chembiochem       Date:  2017-03-23       Impact factor: 3.164

Review 4.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2014-05-26       Impact factor: 10.946

5.  Isolation, Purification, Characterization and Direct Conjugation of the Lipid A-Free Lipopolysaccharide of Vibrio cholerae O139.

Authors:  Peng Xu; Jana Korcová; Peter Baráth; Alžbeta Čížová; Jana Valáriková; Firdausi Qadri; Meagan Kelly; Robert D O'Connor; Edward T Ryan; Slavomír Bystrický; Pavol Kováč
Journal:  Chemistry       Date:  2019-08-20       Impact factor: 5.236

6.  Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines.

Authors:  Peng Xu; Mohammad Murshid Alam; Anuj Kalsy; Richelle C Charles; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan; Pavol Kováč
Journal:  Bioconjug Chem       Date:  2011-09-30       Impact factor: 4.774

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.